Galenica finalizes acquisition of Relypsa

Galenica Group recently announced that its acquisition of Relypsa, Inc. has been completed.

Vifor Pharma, which is owned by Galencia, will be combined with Relypsa to form an important cardio-renal care provider in the United States.

According to the terms of the acquisition, Vifor Pharma will add a fully-incorporated commercial business in the United States.

"By combining the assets, expertise and commercial strengths of Vifor Pharma and Relypsa, Vifor Pharma is well positioned to become a world-leading specialty pharmaceutical company focused on nephrology, cardiology and gastroenterology medicines," Galenica and Vifor Pharma Executive Chairman Etienne Jornod said. "Vifor Pharma's portfolio of specialty products will be further enhanced by gaining full global rights to Veltassa, an important new treatment for people with hyperkalaemia, and by the ability to increase our visibility with leading nephrologists and cardiologists in the U.S. market. With a first class portfolio of products and rapidly growing global commercial presence, Vifor Pharma is committed to being the partner of choice for patients, clinicians and companies in our core therapy areas."

A serious condition, hyperkalaemia, or abnormally elevated levels of potassium in the blood, can lead to life-threatening cardiac arrhythmia and even sudden death.

As previously stated earlier this year, Galenica Group will continue with its plans to divide the company into two independent enterprises. The purchase of Relypsa confirms this strategy.